Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Epcoritamab (GEN3013) is a bispecific IgG1 antibody that redirects T-cells toward CD3×CD20-positive tumor cells, inducing potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Epcoritamab (GEN3013) is a bispecific IgG1 antibody that redirects T-cells toward CD3×CD20-positive tumor cells, inducing potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines [1]. |
In vitro | Epcoritamab, at a concentration of 30 ng/mL, induces effective cytotoxicity in the presence of peripheral blood mononuclear cells (PBMCs) from healthy donors [1]. |
Synonyms | GEN3013 |
Molecular Weight | N/A |
CAS No. | 2134641-34-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Epcoritamab 2134641-34-0 GEN-3013 GEN 3013 GEN3013 inhibitor inhibit